Abstract
Hypoxia is a characteristic feature of many solid tumors which has been described in a wide range of tumor types. Its presence impairs the effectiveness of common anti-cancer therapies and accordingly, tumor hypoxia has been associated with an aggressive tumor phenotype, poor response to radio- and chemotherapy, and worse prognosis. In order to predict outcome and identify patients with a worse prognosis and/or patients that would benefit from appropriate treatments, in vivo measurement of tumor hypoxia is required. Given the difficulties associated with invasive methods, a non-invasive method is of major clinical interest. Although several candidate molecules have been labeled with PET and SPECT labels, none of them is used in daily clinical routine due to a number of difficulties that complicate their use. This review aims to give an overview of the most important hypoxia tracers, their prognostic significance and how these tracers can play a role in tomorrows personalized medicine.
Keywords: Hypoxia, PET, SPECT, nitroimidazole.
Current Pharmaceutical Design
Title:Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Volume: 20 Issue: 14
Author(s): Gilles Mees, Mike Sathekge, Alex Maes and Christophe Van de Wiele
Affiliation:
Keywords: Hypoxia, PET, SPECT, nitroimidazole.
Abstract: Hypoxia is a characteristic feature of many solid tumors which has been described in a wide range of tumor types. Its presence impairs the effectiveness of common anti-cancer therapies and accordingly, tumor hypoxia has been associated with an aggressive tumor phenotype, poor response to radio- and chemotherapy, and worse prognosis. In order to predict outcome and identify patients with a worse prognosis and/or patients that would benefit from appropriate treatments, in vivo measurement of tumor hypoxia is required. Given the difficulties associated with invasive methods, a non-invasive method is of major clinical interest. Although several candidate molecules have been labeled with PET and SPECT labels, none of them is used in daily clinical routine due to a number of difficulties that complicate their use. This review aims to give an overview of the most important hypoxia tracers, their prognostic significance and how these tracers can play a role in tomorrows personalized medicine.
Export Options
About this article
Cite this article as:
Mees Gilles, Sathekge Mike, Maes Alex and Wiele Van de Christophe, Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113196660662
DOI https://dx.doi.org/10.2174/13816128113196660662 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D: A Regulator of Metabolism and Inflammation
Current Nutrition & Food Science Potential Role of Endothelin in Early Vascular Aging
Current Hypertension Reviews Recommendations for the Treatment of Hypertension in Elderly People
Cardiovascular & Hematological Agents in Medicinal Chemistry New Horizons in Diabetes Therapy: The Angiogenesis Paradox in Diabetes: Description of the Problem and Presentation of a Unifying Hypothesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Current Pharmaceutical Design Biomarkers in Unstable Carotid Plaque: Physiopathology and Prediction
Cardiovascular & Hematological Agents in Medicinal Chemistry Glucose Blood Levels as a Therapeutic Target in Acute Ischaemic Stroke Setting
Current Topics in Medicinal Chemistry Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Genetic Polymorphisms of Type-1 and Type-2 Inflammatory Cytokines in Ischaemic Stroke
Vascular Disease Prevention (Discontinued) Relaxin as a Cardiovascular Hormone: Physiology, Pathophysiology and Therapeutic Promises
Cardiovascular & Hematological Agents in Medicinal Chemistry What is the Role for Glycoprotein IIB/IIIA Inhibitor Use in the Catheterization Laboratory in the Current Era?
Current Vascular Pharmacology Secondary Prevention of Ischemic Stroke
Current Drug Targets Impact of Prone Position on Myocardial Perfusion SPECT Interpretation in Women with Suspected Coronary Disease
Current Medical Imaging Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Glucagon Like Peptide-1 and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Epidemiology and Risk Factors of Cerebral Ischemia and Ischemic Heart Diseases: Similarities and Differences
Current Cardiology Reviews Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry